Siegall Clay B Buys 62,500 Shares at Offering Price, Signaling Confidence in Shattuck Labs’ $75 Million Capital Raise

Insider Buying Amid a Surge of Warrants

Shattuck Labs’ most recent filing shows owner Siegall Clay B purchasing 62,500 shares at $4.00 on June 9, 2026, just days before the company’s June 11 public offering is set to close. The trade brings his stake to 318,608 shares—roughly 0.095 % of the outstanding shares—while the overall market price has dipped 12.9 % from the week‑earlier close. This purchase is significant because it occurs at the same price point as the underwritten offering, suggesting that Siegall is aligning his investment with the company’s capital‑raising strategy rather than acting on private information.

What Investors Should Take Away

The timing and size of the buy hint at confidence in the upcoming financing round and the company’s Phase 2b plans for its lead antibody SL‑325. While the stock’s price has declined sharply this month, the issuance of pre‑funded warrants and the underwriter option to buy additional shares signal liquidity support that could help stabilize the share price. For shareholders, the infusion of fresh capital and the potential for future milestone announcements could offset the current valuation drag, but investors should monitor the company’s cash burn and clinical timelines closely.

Siegall Clay B: A Pattern of Opportunistic Participation

Siegall’s historical activity paints a picture of an insider who frequently moves in and out of the company’s equity and warrants. In late May he exercised a 81,000‑share stock option and then bought 128,054 shares at $1.08, doubling his holding to 256,108 shares. Earlier that month he sold an equal amount of warrants, effectively converting option exposure into cash. His recent June purchase mirrors this pattern: he acquires shares at the offering price and then holds them, suggesting a belief that the stock will rebound once the capital structure stabilizes.

Company‑Wide Activity: A Flurry of Warrants and Holdings

The broader insider landscape is dominated by large warrant transactions, especially by ORBIMED ADVISORS LLC and Ashiya Mona, who both bought and sold significant pre‑funded warrant blocks in early August 2025. These movements illustrate a common strategy among biotech insiders: using warrants to hedge exposure while maintaining a long position in the underlying equity. The sheer volume of warrants relative to shares indicates that the company’s capital structure is heavily weighted toward potential future dilution, a factor that should temper short‑term optimism.

Looking Forward

With the June 11 offering closing, Shattuck Labs will have raised approximately $75 million, providing resources to advance its clinical program. Siegall’s latest buy, coupled with the broader insider activity, signals that key stakeholders remain engaged and optimistic about the company’s trajectory. Investors should weigh this insider confidence against the company’s negative price‑earnings ratio and the broader decline in its share price, but the infusion of capital and forthcoming clinical milestones could create a window for upside in the coming quarters.